Eficacia de los fármacos antirreumáticos modificadores de la enfermedad sintéticos en artritis psoriásica: una revisión sistemática

Maese, Jesús; Díaz del Campo, Petra; Seoane-Mato, Daniel; Guerra, Mercedes; Cañete, Juan D.
Reumatol. clín. (Barc.) ; 14(2): 81-89, mar.-abr. 2018. tab, ilus
Artículo en Español | IBECS (España) | ID: ibc-171558

Documentos relacionados

  1. Does daily folic acid supplementation reduce methotrexate efficacy?
  2. Optimising low-dose methotrexate for rheumatoid arthritis-A review.
  3. Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis.
  4. Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients.
  5. Development and validation of a methotrexate adherence assay.
  6. Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial.
  7. [Pharmacogenetics and pharmacogenomics of methotrexate. Current status and novel aspects].
  8. Factors influencing methotrexate and methotrexate polyglutamate in patients with rheumatoid arthritis: a systematic review of population pharmacokinetics.
  9. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.
  10. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.